Benzinga's Top #PreMarket Gainers By: Benzinga via Benzinga April 14, 2014 at 08:12 AM EDT Akebia Therapeutics (NASDAQ: AKBA) shares gained 19.51% to $20.15 in the pre-market. Credit Suisse initiated coverage on the stock with ... Read More >> Related Stocks: Akebia Therapeutics Boston Scientific Edwards Lifesciences JA Solar Holdings, Co., Ltd. - American depositary shares, each representing fiv